DE69010750D1 - Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper. - Google Patents

Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.

Info

Publication number
DE69010750D1
DE69010750D1 DE69010750T DE69010750T DE69010750D1 DE 69010750 D1 DE69010750 D1 DE 69010750D1 DE 69010750 T DE69010750 T DE 69010750T DE 69010750 T DE69010750 T DE 69010750T DE 69010750 D1 DE69010750 D1 DE 69010750D1
Authority
DE
Germany
Prior art keywords
antibodies
fibrin
production
methods
pharmaceutical preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69010750T
Other languages
English (en)
Other versions
DE69010750T2 (de
Inventor
Willem Nieuwenhuizen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Application granted granted Critical
Publication of DE69010750D1 publication Critical patent/DE69010750D1/de
Publication of DE69010750T2 publication Critical patent/DE69010750T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69010750T 1989-05-01 1990-04-26 Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper. Expired - Fee Related DE69010750T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8901102A NL8901102A (nl) 1989-05-01 1989-05-01 Antilichamen tegen fibrine; voor de bereiding van de antilichamen geschikte immunogene peptiden, werkwijze voor het bepalen van fibrine en farmaceutisch preparaat op basis van de antilichamen.

Publications (2)

Publication Number Publication Date
DE69010750D1 true DE69010750D1 (de) 1994-08-25
DE69010750T2 DE69010750T2 (de) 1994-12-22

Family

ID=19854590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69010750T Expired - Fee Related DE69010750T2 (de) 1989-05-01 1990-04-26 Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.

Country Status (8)

Country Link
US (1) US5124439A (de)
EP (1) EP0396188B1 (de)
JP (1) JP2634683B2 (de)
AT (1) ATE108833T1 (de)
DE (1) DE69010750T2 (de)
DK (1) DK0396188T3 (de)
ES (1) ES2060927T3 (de)
NL (1) NL8901102A (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009034A1 (en) * 1992-10-12 1994-04-28 Agen Limited Clot directed anticoagulant, process for making same and methods of use
EP0678524B1 (de) * 1993-11-02 2008-02-06 Mitsubishi Kagaku Iatron, Inc. Antikörper gegen menschliches lösliches fibrin, hybridome, die sie produzieren und immunmessverfahren
AU709134B2 (en) * 1994-05-02 1999-08-19 E.R. Squibb & Sons, Inc. Recombinant fibrin chains, fibrin and fibrin-homologs
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
US9814672B2 (en) 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung

Also Published As

Publication number Publication date
DE69010750T2 (de) 1994-12-22
EP0396188A1 (de) 1990-11-07
EP0396188B1 (de) 1994-07-20
JPH0348159A (ja) 1991-03-01
ES2060927T3 (es) 1994-12-01
NL8901102A (nl) 1990-12-03
DK0396188T3 (da) 1994-08-22
ATE108833T1 (de) 1994-08-15
US5124439A (en) 1992-06-23
JP2634683B2 (ja) 1997-07-30

Similar Documents

Publication Publication Date Title
Marder et al. High Molecular Weight Derivatives of Human Fibrinogen Produced by Plasmin: III. THEIR NH2-TERMINAL AMINO ACIDS AND COMPARISON WITH THE “NH2-TERMINAL DISULFIDE KNOT
ATE92107T1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
DE3586402D1 (de) Proteinzusammensetzung mit koagulations-wirkung und verfahren zu ihrer herstellung.
DE3856265D1 (de) Varianten des pankreatischen Rinder-Trypsininhibitors, deren Herstellung und Verwendung
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE373010T1 (de) Gag-antigen und dessen verwendung zum nachweis von lav-infektion, sowie in immunogenen zusammensetzungen
ATE145241T1 (de) Polypeptid, das zur interaktion mit thrombin fähig ist
DE68928728D1 (de) Diagnose von retinoblastoma
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69010750D1 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
SE8902148L (sv) Syntetiska peptid antigen foer detektion av htlv-1 infektion
ATE115188T1 (de) Antikörper gegen fibrin, immunogen zur herstellung desselben, verfahren zur bestimmung von fibrin und pharmazeutisches präparat auf basis der antikörper.
DE69032323D1 (de) Produktion und verwendung von antihelmintischen substanzen und schützenden immunogenen
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
DE69121489D1 (de) In vitro-Behandlung von Fusionsproteinen
ATE110775T1 (de) Verfahren zur herstellung von hirudin.
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
DE60041985D1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen
DD133231A1 (de) Verfahren zur herstellung von peptiden,proteinen und proteinsequenzen
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.
DE3485972D1 (de) Antigen aktive aminosaeuresequenzen.
ATE51154T1 (de) Antithrombogenes, nichtcalcifizierendes material und ein verfahren zur herstellung von gegenstaenden fuer medizinische zwecke.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee